Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Middle East respiratory syndrome wikipedia , lookup
Marburg virus disease wikipedia , lookup
Orthohantavirus wikipedia , lookup
West Nile fever wikipedia , lookup
Influenza A virus wikipedia , lookup
Hepatitis B wikipedia , lookup
Henipavirus wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Incidence of Latent Virus Shedding During Space Flight Satish K. Mehta1, Randall J. Cohrs2, Donald H. Gilden2, Steven K. Tyring3, C. Mark Ott4, and Duane L. Pierson4 1 Enterprise Advisory Services, Incorporated, Houston, TX 2 University of Colorado Health Sciences, Denver, CO 3 University of Texas Health Science Center, Houston, TX 4 NASA Johnson Space Center, Houston, TX Measurements of immune parameters of both cellular and innate immunity indicate alterations in immune function in astronauts. Immune changes may be the response to stress associated with launch, flight, and landing phases. Medical relevance of observed changes is not known. The reactivation of latent viruses has been identified as an important in vivo indicator of clinically relevant immune changes. The polymerase chain reaction (PCR) was used to detect the presence of specific viral DNA. Initial studies demonstrated Epstein-Barr virus (EBV) reactivation during all 3 mission phases. EBV is shed in saliva following reactivation from B-cells. Incidence of EBV in saliva was several fold higher than controls during all 3 mission phases. However, quantitative PCR revealed 10-fold higher levels of EBV DNA present in saliva collected during flight than found in pre- and post flight specimens. To determine if other latent viruses showed similar effects, cytomegalovirus (CMV), another herpes virus, shed in urine following reactivation was studied. A very low incidence (<2%) of CMV in urine is found in healthy, low-stressed individuals. However, 25-50 % of astronauts shed CMV in their urine before, during, or after flight. Our studies are now focused on varicella-zoster virus (VZV), the etiological agent of both chicken-pox during childhood and shingles later in life. We demonstrated reactivation of VZV and shedding of the virus during and after spaceflight in saliva of astronauts with no sign of active infection or symptoms. The maximum shedding of VZV occurred during the flight phase and diminishes rapidly during the first five days after landing. We have utilized the PCR assay for VZV in a clinical study with shingles patients. Generally, shingles patients shed much more VZV in saliva than astronauts. However, the VZV levels in astronauts overlap the lower range of VZV numbers in shingles patients. The question of infectivity of shed virus was answered by culturing saliva immediately after landing. Successful culturing of VZV on monolayer of human fetal lung fibroblast cells and subsequent staining with VZV specific stain confirmed that the VZV that reactivate during spaceflight was live and infectious. We have concluded that latent viruses do reactivate before, during, and after spaceflight. This is consistent with previous findings of diminished immunity; specifically cell mediated immune response, and reactivation and shedding tend to increase with length of mission. Future plans will be focused on the clinical risk posed by the reactivation of these viruses. Initial efforts will determine the effect of longer missions on the International Space Station on the reactivation patterns of these viruses.